OA11870A - Synergistic effects of amlodipine and atorvastatin. - Google Patents

Synergistic effects of amlodipine and atorvastatin. Download PDF

Info

Publication number: OA11870A
Authority: OA; OAPI
Prior art keywords: pharmaceutical composition; amlodipine; atorvastatin; blood pressure; métabolite
Prior art date: 1999-04-23

Application number

OA1200100272A

Other languages

English (en)

Inventor

Mason R Robert

Original Assignee

Mason R Robert

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-23

Filing date

2000-04-18

Publication date

2006-03-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-04-18 Application filed by Mason R Robert filed Critical Mason R Robert

2006-03-27 Publication of OA11870A publication Critical patent/OA11870A/en

Links

229960000528 amlodipine Drugs 0.000 title claims abstract description 122
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims abstract description 32
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims abstract description 25
229960005370 atorvastatin Drugs 0.000 title claims abstract description 25
230000002195 synergetic effect Effects 0.000 title claims abstract description 19
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 3
239000012528 membrane Substances 0.000 claims abstract description 59
108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 32
102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 32
230000003859 lipid peroxidation Effects 0.000 claims abstract description 14
208000029078 coronary artery disease Diseases 0.000 claims abstract description 11
230000001225 therapeutic effect Effects 0.000 claims abstract description 10
241000282414 Homo sapiens Species 0.000 claims abstract description 8
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 130
150000002632 lipids Chemical class 0.000 claims description 54
239000008194 pharmaceutical composition Substances 0.000 claims description 54
239000003814 drug Substances 0.000 claims description 31
208000019622 heart disease Diseases 0.000 claims description 25
230000036772 blood pressure Effects 0.000 claims description 24
201000001320 Atherosclerosis Diseases 0.000 claims description 19
238000000034 method Methods 0.000 claims description 17
230000003647 oxidation Effects 0.000 claims description 14
238000007254 oxidation reaction Methods 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 13
230000002829 reductive effect Effects 0.000 claims description 13
206010020772 Hypertension Diseases 0.000 claims description 9
206010002383 Angina Pectoris Diseases 0.000 claims description 7
229960004005 amlodipine besylate Drugs 0.000 claims description 7
206010003210 Arteriosclerosis Diseases 0.000 claims description 6
206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
206010019280 Heart failures Diseases 0.000 claims description 6
208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
208000006011 Stroke Diseases 0.000 claims description 6
208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
208000010125 myocardial infarction Diseases 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 5
230000009885 systemic effect Effects 0.000 claims 23
238000009472 formulation Methods 0.000 claims 3
230000002401 inhibitory effect Effects 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 32
230000003078 antioxidant effect Effects 0.000 abstract description 32
230000000694 effects Effects 0.000 abstract description 29
239000003963 antioxidant agent Substances 0.000 abstract description 17
235000006708 antioxidants Nutrition 0.000 abstract description 17
229930003427 Vitamin E Natural products 0.000 abstract description 16
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 16
239000011709 vitamin E Substances 0.000 abstract description 16
235000019165 vitamin E Nutrition 0.000 abstract description 16
229940046009 vitamin E Drugs 0.000 abstract description 16
230000005764 inhibitory process Effects 0.000 abstract description 12
150000003904 phospholipids Chemical class 0.000 abstract description 12
238000004458 analytical method Methods 0.000 abstract description 10
239000000126 substance Substances 0.000 abstract description 10
239000000890 drug combination Substances 0.000 abstract description 7
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 6
238000002441 X-ray diffraction Methods 0.000 abstract description 6
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 6
238000002648 combination therapy Methods 0.000 abstract description 5
238000012986 modification Methods 0.000 abstract description 5
230000004048 modification Effects 0.000 abstract description 5
230000001590 oxidative effect Effects 0.000 abstract description 5
208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
150000001875 compounds Chemical class 0.000 abstract description 4
230000006378 damage Effects 0.000 abstract description 4
235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 4
210000005167 vascular cell Anatomy 0.000 abstract description 4
230000004001 molecular interaction Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 description 28
238000011282 treatment Methods 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 12
150000003254 radicals Chemical class 0.000 description 11
229940127291 Calcium channel antagonist Drugs 0.000 description 10
230000003993 interaction Effects 0.000 description 9
239000000480 calcium channel blocker Substances 0.000 description 8
-1 lipid peroxide Chemical class 0.000 description 8
238000005502 peroxidation Methods 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
239000000232 Lipid Bilayer Substances 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
239000011575 calcium Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 6
229960003912 probucol Drugs 0.000 description 6
230000008901 benefit Effects 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000004792 oxidative damage Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000036523 atherogenesis Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940036132 norvasc Drugs 0.000 description 4
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
239000004322 Butylated hydroxytoluene Substances 0.000 description 3
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
240000001970 Raphanus sativus var. sativus Species 0.000 description 3
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 3
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000003143 atherosclerotic effect Effects 0.000 description 3
235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
229940095259 butylated hydroxytoluene Drugs 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
229960004844 lovastatin Drugs 0.000 description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 3
229950009116 mevastatin Drugs 0.000 description 3
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 3
230000037361 pathway Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002792 vascular Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
208000014882 Carotid artery disease Diseases 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000017170 Lipid metabolism disease Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
241000288906 Primates Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
208000032594 Vascular Remodeling Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
230000000489 anti-atherogenic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
208000037876 carotid Atherosclerosis Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
238000007887 coronary angioplasty Methods 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000009223 neuronal apoptosis Effects 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
238000001988 small-angle X-ray diffraction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
229940122642 Calcium channel agonist Drugs 0.000 description 1
XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
108090001069 Chymopapain Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100492797 Mus musculus Atmin gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000028922 artery disease Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000000801 calcium channel stimulating agent Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000000782 cerebellar granule cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
238000006356 dehydrogenation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
229940124642 endogenous agent Drugs 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
210000004565 granule cell Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003999 initiator Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000011546 protein dye Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
238000004835 semi-empirical calculation Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200100272A 1999-04-23 2000-04-18 Synergistic effects of amlodipine and atorvastatin. OA11870A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US13066599P	1999-04-23	1999-04-23
US14530599P	1999-07-23	1999-07-23
US15112199P	1999-08-27	1999-08-27
US16659299P	1999-11-19	1999-11-19

Publications (1)

Publication Number	Publication Date
OA11870A true OA11870A (en)	2006-03-27

Family

ID=27494873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100272A OA11870A (en)	1999-04-23	2000-04-18	Synergistic effects of amlodipine and atorvastatin.

Country Status (30)

Country	Link
EP (1)	EP1173172B1 (de)
JP (1)	JP2002542289A (de)
KR (1)	KR20020024581A (de)
CN (1)	CN1351492A (de)
AP (1)	AP2001002324A0 (de)
AT (1)	ATE314846T1 (de)
AU (1)	AU4647000A (de)
BG (1)	BG106115A (de)
BR (1)	BR0010689A (de)
CA (1)	CA2370639A1 (de)
CZ (1)	CZ20013793A3 (de)
DE (1)	DE60025344T2 (de)
DK (1)	DK1173172T3 (de)
EA (1)	EA004435B1 (de)
EE (1)	EE200100555A (de)
ES (1)	ES2256005T3 (de)
HK (1)	HK1043741A1 (de)
HU (1)	HUP0201016A3 (de)
IL (1)	IL146085A0 (de)
IS (1)	IS6118A (de)
NO (1)	NO20015128L (de)
OA (1)	OA11870A (de)
PE (1)	PE20010055A1 (de)
PL (1)	PL351408A1 (de)
PT (1)	PT1173172E (de)
SK (1)	SK15382001A3 (de)
SV (1)	SV2002000058A (de)
TN (1)	TNSN00085A1 (de)
UY (1)	UY26118A1 (de)
WO (1)	WO2000064443A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
CN100430057C (zh) *	2005-04-08	2008-11-05	石药集团中奇制药技术（石家庄）有限公司	左旋氨氯地平和阿托伐他汀的药物组合物
KR101467110B1 (ko) *	2013-08-01	2014-11-28	한국방송공사	코로나링을 구비한 지선애자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5385929A (en) *	1994-05-04	1995-01-31	Warner-Lambert Company	[(Hydroxyphenylamino) carbonyl] pyrroles
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.

2000
- 2000-04-18 DK DK00928200T patent/DK1173172T3/da active
- 2000-04-18 IL IL14608500A patent/IL146085A0/xx unknown
- 2000-04-18 DE DE60025344T patent/DE60025344T2/de not_active Expired - Fee Related
- 2000-04-18 HU HU0201016A patent/HUP0201016A3/hu unknown
- 2000-04-18 BR BR0010689-5A patent/BR0010689A/pt not_active IP Right Cessation
- 2000-04-18 AP APAP/P/2001/002324A patent/AP2001002324A0/en unknown
- 2000-04-18 AU AU46470/00A patent/AU4647000A/en not_active Abandoned
- 2000-04-18 EE EEP200100555A patent/EE200100555A/xx unknown
- 2000-04-18 AT AT00928200T patent/ATE314846T1/de not_active IP Right Cessation
- 2000-04-18 KR KR1020017013547A patent/KR20020024581A/ko not_active Withdrawn
- 2000-04-18 EA EA200101112A patent/EA004435B1/ru not_active IP Right Cessation
- 2000-04-18 SK SK1538-2001A patent/SK15382001A3/sk unknown
- 2000-04-18 CN CN00807935A patent/CN1351492A/zh active Pending
- 2000-04-18 CZ CZ20013793A patent/CZ20013793A3/cs unknown
- 2000-04-18 EP EP00928200A patent/EP1173172B1/de not_active Expired - Lifetime
- 2000-04-18 WO PCT/US2000/010465 patent/WO2000064443A1/en not_active Ceased
- 2000-04-18 CA CA002370639A patent/CA2370639A1/en not_active Abandoned
- 2000-04-18 PL PL00351408A patent/PL351408A1/xx unknown
- 2000-04-18 HK HK02105343.1A patent/HK1043741A1/zh unknown
- 2000-04-18 PT PT00928200T patent/PT1173172E/pt unknown
- 2000-04-18 JP JP2000613434A patent/JP2002542289A/ja not_active Withdrawn
- 2000-04-18 ES ES00928200T patent/ES2256005T3/es not_active Expired - Lifetime
- 2000-04-18 OA OA1200100272A patent/OA11870A/en unknown
- 2000-04-19 PE PE2000000374A patent/PE20010055A1/es not_active Application Discontinuation
- 2000-04-21 TN TNTNSN00085A patent/TNSN00085A1/fr unknown
- 2000-04-24 UY UY26118A patent/UY26118A1/es unknown
- 2000-04-25 SV SV2000000058A patent/SV2002000058A/es unknown
2001
- 2001-10-19 IS IS6118A patent/IS6118A/is unknown
- 2001-10-19 NO NO20015128A patent/NO20015128L/no not_active Application Discontinuation
- 2001-11-16 BG BG106115A patent/BG106115A/bg unknown

Also Published As

Publication number	Publication date
AU4647000A (en)	2000-11-10
EP1173172A4 (de)	2002-08-07
DE60025344D1 (de)	2006-03-30
HUP0201016A2 (hu)	2002-07-29
TNSN00085A1 (fr)	2005-11-10
EA004435B1 (ru)	2004-04-29
NO20015128L (no)	2001-12-20
WO2000064443A1 (en)	2000-11-02
SK15382001A3 (sk)	2002-05-09
BR0010689A (pt)	2002-02-19
CZ20013793A3 (cs)	2002-05-15
PT1173172E (pt)	2006-05-31
NO20015128D0 (no)	2001-10-19
EE200100555A (et)	2002-12-16
KR20020024581A (ko)	2002-03-30
AP2001002324A0 (en)	2001-12-31
ATE314846T1 (de)	2006-02-15
HUP0201016A3 (en)	2003-03-28
IL146085A0 (en)	2002-07-25
BG106115A (bg)	2002-11-29
EP1173172B1 (de)	2006-01-04
EA200101112A1 (ru)	2002-06-27
PL351408A1 (en)	2003-04-22
ES2256005T3 (es)	2006-07-16
UY26118A1 (es)	2001-03-16
PE20010055A1 (es)	2001-01-30
CA2370639A1 (en)	2000-11-02
DK1173172T3 (da)	2006-05-15
EP1173172A1 (de)	2002-01-23
IS6118A (is)	2001-10-19
HK1043741A1 (zh)	2002-09-27
DE60025344T2 (de)	2006-09-28
JP2002542289A (ja)	2002-12-10
CN1351492A (zh)	2002-05-29
SV2002000058A (es)	2002-02-05
WO2000064443A9 (en)	2002-08-29

Publication	Publication Date	Title
US7129265B2 (en)	2006-10-31	Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
Suzumura et al.	1999	Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro
Hussein et al.	1997	Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
Napoli et al.	2004	Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension
Menéndez et al.	2000	Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
KR100539644B1 (ko)	2005-12-29	지단백질 산화의 억제
Libby et al.	2000	Lipid lowering improves endothelial functions
Plane et al.	1993	Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins
US20020052394A1 (en)	2002-05-02	Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
KR20130004942A (ko)	2013-01-14	부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
Mason	2005	A rationale for combination therapy in risk factor management: a mechanistic perspective
Sherratt et al.	2019	Rosmarinic acid and its esters inhibit membrane cholesterol domain formation through an antioxidant mechanism based, in nonlinear fashion, on alkyl chain length
Berkels et al.	2005	Different antioxidative potencies of dihydropyridine calcium channel modulators in various models
EP1173172B1 (de)	2006-01-04	Synergistische wirkungen von amlodipin und dem hydroxylierten metabolit von atorvastatin
Jorge et al.	1997	Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin
SUZUMURA et al.	2000	Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein
Haller et al.	2002	Endothelial dysfunction, hypertension and atherosclerosis: a review of the effects of lacidipine
Fleckenstein-Grün et al.	1994	Role of calcium in arteriosclerosis—experimental evaluation of antiarteriosclerotic potencies of Ca antagonists
Bernini et al.	1997	Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies
JP2002542289A5 (de)	2007-06-07
MXPA01010694A (en)	2002-06-05	Synergistic effects of amlodipine and atorvastatin
Grieve et al.	2000	Chylomicron remnants potentiate phenylephrine-induced contractions of rat aorta by an endothelium-dependent mechanism
Khanderia et al.	2011	The ezetimibe controversy: implications for clinical practice
Ohmori et al.	2004	Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits
MXPA00003200A (en)	2001-05-17	Inhibtion of lipoprotein oxidation